State Street
FENC icon

State Street’s Fennec Pharmaceuticals FENC Stock Holding History

State Street’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.21M Buy
359,055
+6,280
+2% +$48.5K ﹤0.01% 3274
2025
Q4 		$2.72M Buy
352,775
+11,574
+3% +$95K ﹤0.01% 3238
2025
Q3 		$3.19M Buy
341,201
+4,707
+1% +$40.7K ﹤0.01% 3177
2025
Q2 		$2.79M Sell
336,494
-1,639
-0.5% -$11.2K ﹤0.01% 3193
2025
Q1 		$2.06M Sell
338,133
-1,580
-0.5% -$10.1K ﹤0.01% 3238
2024
Q4 		$2.15M Buy
339,713
+11,454
+3% +$58.7K ﹤0.01% 3296
2024
Q3 		$1.64M Buy
328,259
+7,053
+2% +$40.8K ﹤0.01% 3383
2024
Q2 		$1.96M Buy
321,206
+17,687
+6% +$147K ﹤0.01% 3326
2024
Q1 		$3.38M Buy
303,519
+37,869
+14% +$380K ﹤0.01% 3092
2023
Q4 		$2.98M Buy
265,650
+4,216
+2% +$34.9K ﹤0.01% 3169
2023
Q3 		$1.96M Sell
261,434
-51
-0% -$415 ﹤0.01% 3348
2023
Q2 		$2.31M Buy
+261,485
New +$2.17M ﹤0.01% 3346
2021
Q2 		– Sell
-327,151
Closed -$2.03M – 4475
2021
Q1 		$2.03M Sell
327,151
-13,900
-4% -$105K ﹤0.01% 3431
2020
Q4 		$2.54M Buy
341,051
+12,745
+4% +$97.1K ﹤0.01% 3269
2020
Q3 		$1.99M Buy
328,306
+46,438
+16% +$327K ﹤0.01% 3199
2020
Q2 		$2.35M Buy
+281,868
New +$2.1M ﹤0.01% 3121
2019
Q2 		– Sell
-167,372
Closed -$812K – 3830
2019
Q1 		$812K Buy
167,372
+5,454
+3% +$35.9K ﹤0.01% 3375
2018
Q4 		$1.03M Buy
161,918
+6,193
+4% +$43.3K ﹤0.01% 3322
2018
Q3 		$1.28M Buy
155,725
+7,400
+5% +$68.6K ﹤0.01% 3365
2018
Q2 		$1.55M Buy
+148,325
New +$1.76M ﹤0.01% 3340

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's FENC Position: Q1 2026 in Review

State Street increased its Fennec Pharmaceuticals (FENC) stake by 1.8% in Q1 2026, buying an estimated $48.5K and bringing the position to 359,055 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3274.

State Street first reported a position in FENC in Q2 2018 and has held it in 20 quarters since. The position peaked at $3.38M in Q1 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • State Street held 359,055 shares of Fennec Pharmaceuticals worth $2.21M as of Q1 2026.
  • State Street bought 6,280 Fennec Pharmaceuticals shares in Q1 2026, an estimated $48.5K.
  • Fennec Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3274 holding.
  • State Street first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 20 quarters since.
  • State Street's Fennec Pharmaceuticals position peaked at $3.38M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.